Introduction

In 2012, Alzheimer Europe had an audited income of EUR 1.246,211.94 of which EUR 619,177.75 (49.68%) were for the organisation’s core activities (including the organisation’s Dementia Ethics Network and EUR 627,034.19 (50.32%) were for the organisation’s annual conference, corporate affairs activities and other projects.

Funding of core activities (EUR 619,177.75)

In 2012, the core funding of Alzheimer Europe was composed as follows:

• EUR 235,603.94 (38.05%) from public funding,
• EUR 149,272.10 (24.11%) from member organisations,
• EUR 141,755.83 (22.89%) from foundations and other non-profit organisations,
• EUR 70,335.64 (11.36%) from deferred income brought forward from the financial year 2011,
• EUR 7,840.37 (1.27%) from corporate sources,
• EUR 2,073.19 (0.33%) from bank interest and similar,
• EUR 1,210.62 (0.20%) from individuals,
• EUR 11,086.06 (1.79%) from other sources.

Public funding

In 2012, the breakdown of public funding totalling EUR 235,603.94 can be broken down as follows:

• Alzheimer Europe received EUR 190,000 as an operating grant from the European Commission, EUR 20,889 for its participation in the DECIDE project, EUR 17,725.28 for its participation in the PharmaCog project and EUR 6,989.66 for its participation in the NILVAD project.

Funding from member organisations

In 2012, the EUR 149,272.10funding from member organisations can be broken down as follows:

• EUR 60,874.39 in membership fees and contributions
• EUR 58,391.66 from the Luxembourg member organisation through the secondment of the AE Executive Director,
• EUR 12,000 from the Luxembourg member organisation by providing the offices of Alzheimer Europe free of rent,
• EUR 16,500 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day) and
• EUR 1,506.05 from Alzheimer Scotland as support to the preparatory meeting of the European Working Group of People with Dementia in Glasgow.

Foundations and organisations

The EUR 141,755.83 which Alzheimer Europe received in 2012 from foundations and other non-profit organisations can be broken down as follows:

• EUR 68,260 from Alzheimer Europe Foundation which supported the organisation’s Dementia in Europe Yearbook and European Dementia Ethics Network,
• EUR 39,300 in donated time by experts involved in the ethical work and comparison of national dementia strategies of Alzheimer Europe (at EUR 300 per day),
• EUR 29,195.83 as direct support from Fondation Alzheimer, Luxembourg and
• EUR 5,000 from Fondation Médéric Alzheimer which supported the European Dementia Ethics Network.

Deferred income

In 2012, Alzheimer Europe was able to contribute EUR 70,335.64 to its core activities which came from deferred income in 2011.

Corporate support

In 2012, Alzheimer Europe received EUR 7,840.37 from corporate sources as core-funding which can be broken down as follows:

• EUR 6,000 from Mazars which carried out the audit of the organisation’s 2011 and 2012 accounts free of charge,
• EUR 1,650 from Newswweaver which provided an e-mail facility free of charge and
• EUR 190.37 as a donation from Mark Krueger and Associates.

Bank interest and similar

In 2012, Alzheimer Europe had an income of EUR 2,073.19 from bank interest and similar income.

Individuals

In 2012, AE received EUR 1,210.62 from individuals which can be broken down as follows:

• EUR 1,090.62 in publication sales and
• EUR 120 in donations.

Other income

In 2012, EUR 11,086.06 came from other sources not mentioned above.

Funding of project activities (EUR 627,034.19)

In 2012, Alzheimer Europe received EUR 627,034.19 for its various projects, including its Annual Conference in Vienna, the Alzheimer Europe Foundation and its corporate affairs activities, of which

• EUR 317,680.07 (50.66%) came from corporate sponsors

• EUR 120,000 (19.14%) from deferred income brought forward from the financial year 2011,
• EUR 112,854.12 (18.00%) from private individuals,
• EUR 62,500 (9.97%) from public sources and
• EUR 14,000 (2.23%) from foundations and other non-profit organisations.

Corporate support

The corporate support received by Alzheimer Europe for its activities in 2012 (EUR 317,680.08) can be broken down as follows:

• Janssen and Lilly each contributed EUR 50,000 towards AE’s corporate activities and the Annual Conference in Vienna,
• Pfizer and Novartis contributed EUR 40,000 towards AE’s corporate activities,
• GlaxoSmithKline contributed EUR 35,000 in support,
• GE Healthcare provided EUR 30,000 in support of AE’s corporate activities and the Annual Conference in Vienna,
• SCA Global Hygiene contributed EUR 20,000 towards AE’s corporate activities and the Annual Conference in Vienna,
• Nutricia contributed EUR 20,000 towards AE’s Annual Conference in Vienna,
• Lundbeck contributed EUR 10,000 towards AE’s corporate activities.

In addition, AE received EUR 879.51 in travel support from Pfizer and EUR 1,782.56 as travel support and honoraria from GlaxoSmithKline.

Deferred income

In 2012, Alzheimer Europe was able to dedicate EUR 120,000 for the setting up of the Alzheimer Europe Foundation. This funding came from deferred income in 2011.

Private individuals

In 2012, Alzheimer Europe received EUR 112,854.12 in registration fees for the Alzheimer Europe Conference in Vienna.

Public funding

In 2012, Alzheimer Europe received EUR 60,000 as a grant from the European Commission and EUR 2,500 from Land Niederösterreich for its Annual Conference in Vienna.

Foundations and non-profit organisations

In 2012, Alzheimer Europe received EUR 10,000 from the Network of European Foundations and EUR 4,000 from Fondation Roi Baudouin for its Annual Conference in Vienna.

Overall funding

The following table lists all sources of income received in 2012.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.